BeyondSpring

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Multiple biotech companies raise significant funds for various medical advancements, including $600M for Symbiotic Capital targeting biotechnology, medical devices, diagnostics, and synthetic biology; $165M Series A for Third Arc Bio's multifunctional antibodies for oncology and autoimmunity; $144M Series B for Outpace Bio's AI-powered cell therapies for solid tumors; and others ranging from $126M for Halda Therapeutics' RIPTAC cancer therapies to $5M for Kano Therapeutics' targeted, non-viral DNA insertion technology.